Cancer Genetics, Inc. (CGIX) belongs to the Healthcare sector with an industry focus on Medical Laboratories & Research, with Mr. Panna Sharma as Chief Exec. Officer, Pres and Director.

The company has been one of the biggest innovators in Medical Laboratories & Research employing approximately 223 full time employees.

Key Statistics:

Financials:

The company reported an impressive total revenue of 27.05 Million in the last fiscal year.

If you look at the companys income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, CGIX earned gross profit of 1.75 Million, in 2015 3.94 Million gross profit, while in 2016 Cancer Genetics, Inc. (CGIX) produced 9.95 Million profit.

Currently the shares of Cancer Genetics, Inc. (CGIX) has a trading volume of 1.87 Million shares, with an average trading volume of 970625 shares with shares dropping to a 52 week low of $1.1 on Nov 4, 2016, and the companys shares hitting a 52 week high on Mar 24, 2017 of $3.95.

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Down in the future.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Cancer Genetics, Inc. the EPS stands at -0.23 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.28, suggesting the stock exceeded the analysts expectations.

Another critical number in evaluating a stock is P/E or the price to earnings ratio.

The TTM operating margin is -65.9%. The return on invested capital at -54.5%, which is good, compared to its peers.

The Free Cash Flow or FCF margin is 0%, which means that the business has healthy reserve funds for contingencies that may arise.

Stock is currently moving with a positive distance from the 200 day simple moving average of approximately 103.68%, and has a solid year to date (YTD) performance of 188.89% which means the stock is constantly adding to its value from the previous fiscal year end price.

Future Expectations:

The target price for Cancer Genetics, Inc. (CGIX) is $6/share according to the consensus of analysts working on the stock, with an expected EPS of $-0.22/share for the current quarter.

The companys expected revenue in the current quarter to be 7.1 Million, seeing a projected current quarter growth of 53.2%, and per annum growth estimates over the next 5 year period of around 40%.

Original post:
Cancer Genetics, Inc. closed with a change of 16.42% in the Previous Trading Session - Free Observer